ANZBMS 2019 Michael McClung
Oregon Osteoporosis Center, OR, United States
- This delegate is presenting an abstract at this event.
Presentations this author is a contributor to:
A pooled analysis of fall incidence from placebo-controlled trials of denosumab (#89)
5:55 PM
Jeffrey Hassall
Welcome Reception and Plenary Posters
Subject characteristics and changes in bone mineral density after transitioning from denosumab to alendronate in the denosumab adherence preference satisfaction (DAPS) study (#74)
10:12 AM
Mike McClung
Session 7 – Bone Health in the Disadvantaged